Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib. Cerdulatinib is a dual inhibitor of the Janus kinase (JAK) and spleen tyrosine kinase (Syk) pathways, which Dermavant is evaluating as a differentiated topical treatment option for vitiligo and other inflammatory skin conditions such as atopic dermatitis.

Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Chris Chapman as Chief Commercial Officer. Mr. Chapman brings extensive commercial expertise in dermatology and over 20 years of leadership experience in the biopharmaceutical industry.

Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, announced today that it has entered into a collaboration and license agreement with Japan Tobacco Inc. (JT) for exclusive rights to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis. Along with this agreement, JT has signed an exclusive license agreement with its subsidiary, Torii Pharmaceutical Co., Ltd. (Torii), for co-development and commercialization of tapinarof in Japan.